In prepuberty absence of Lti pulses may be real or due to insensitivity of the LH assay. LH patterns were studied in healthy boys yr,BA:ll.O-11.5 yr,test.vol.(~v)<3 ml and 11 early pub. CA:11.5-13.4 yr, BA:11.0-12.5 yr, Tanner stage G2, TV)3 ml).Informed consent was obtained. Blood for LH estimation was sampled at 10' intervals from 12-10 hr and from 24-06 hr. A duoclonal IRMA, specific for LH wlth a sensitivity of 0.10 ~/ 1 (MAIAclone Serono) was used. In the G1 boys LA was not detectable during daytime; at night during periods of 20-60' detectable but low (<O.5 U/1) values were observed. In the G2 boys most diurnal values were> 0.3 ~/ 1 with periods of values of 0.1-0.3 U/1; in 5 boys occasional pulses (<1.0 u/1 were observed. At night deflnite pulses up to 3 U/1 were observed In all boys; the median number of pulses was 4/6 hr.Conclusion: at the onset of puberty the still prepubertal boy has intermittant gonadotrophic activlty only during the n~g h t ; in early puberty thls actlvity increases to a clear pulsL%tlle Previously published information on GH metabolism in GH-deficient patients is scarce and data are conflicting. We studied the metabolic clearance r'ate (MCR), plasma half-life and apparent distribution space (DS) of unlabelled 'methionlne free1-biosynthetic human growth hormone (B-hGH) using the constant infusion technique in seven hypopituitary patients, 6 males and 1 female, mean age 21 years (range 15-29 years). They received a constant intravenous infusion of B-hGt1 with a rate of 50 ng/kg/min for three hours. After stopping the infusion the disappearance of se-growth hormone was followed for another three hours. The MCR averaged 4.06 ml/kg/min t 1.11 (SEM) . T1/2 was estimated by means of linear regression analysis, the mean value was 21.3 min t 2.14 (SEM). The elimination was found to follow first order Tinetics. The DS averaged 117.63 ml/kg t 26.93 (GEM) . The present results demonstrate that the kinetic; of B-hGH elimination is of first order and further that T1/2 is of the same range as described in normal subjects. In a double-blind crossover study we coliipared pituitary and 'olethioni ne free' biosynthetic huiiian growth horiiione (P-hGH and B-hGH) with respect to phariiiacoki netics and short temi nietabolic effects in 9 hypopi tui tary chi ldreA.~hey treated themselves for 4 weeks with 2 IU subcutaneously (s.c.1 daily at 20.00h. After admittance to hospital 2 IU was given intramusculary (i.in.) the first day, and s.c. the second.They then switched over to the alternative preparation.The pharniacokinetics of B-and P-hGH were identical. Comparing i.m. and 5.c. absorption ,the latter was slower,and resulted in smaller areas under the curves,indicating greater local degradation.Both preparations caused identical increases in somatomedin C,but slightly more sustained after s .~. inj.P-glucose, -glukagon and s-insulin fluctuated within normal range.The glucose profile pointed at a niodest anti-insulin effect of hGH when given in the morning.5-lactate,-alanine,-glycerol and -B-OH-butyrate,and s-TG,-cholesterol and -carbaoiide revealed no abnormalities with either hGH preparation.Finally,no developli~ent of anti-GH or E coli polypeptide'antibodies was seen.1~ conclusion, the pharmacoki neti cs and short term metabolic effects of 0-hGH and P-hGH were identical.Furthermore,the advantage of daily S.C. hGH injections in the evening is once more deinonstrated.
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hGI1 administration to children with GllD i s associated with increased bone turnover and tubular phosphate (P) reabsorption. Both mechanisms a r e important for enhenced somatic growth and may be regulated by other factors than Gli o r SM-C. W e therefore studied the role of M-CT, the biological active form o f calcitonin, a s a possible mediator of hGII o n P and bone metabolism. C a stimulated (2mg/kg/5min iv) CT-M (ACT-M) was measured with a new silica extraction method before and during hGH replacement i n 8 prepubertal children w i t h G H D in comparison to 16 controls (C) and Bconstitutional tall children (T).AM-CT mean's^^) was 36210 in untreated GfID, 2'Ik4 i n C, and 14*4 pg/ml in T (GIID v s T, P(O.05).
During treatment with 2u/m2/d s c hG1tAM-CT decreased significantly in G H D to 16*4 pg/ml after 1 month, remaining suppressed durlng 1 2 months. hG11 induced a parallel increase of growth rate, alkaline phosphatase, osteocalcin, urlne hydroxyproline and tubular transport maximum for P (TmP/GFR), the latter keing negatively related toAl4-CT (r=-0.47, n=32,P<0.01). Conclusion: hGII suppresses M-CT secretion, explaining i n part its increasing effect o n bone turnover and renal phosphate conservation. Adult height of hypopituitary children following treatment with human pltuitary growth hormone (hGH) is disappointingly low desplte the fact that hCH admlnistration before puberty results in accelerated statural growth without unduly accelerating bone maturation. Our study showed that the range of adult heights was similar for various types of hypopituitary growth retardation; thls range did not undergo an appreciable upward shift after hGH treatment.
Evaluation of hCH effectiveness for a well-deflned type, that of multiple pituitary hormone deficiency following breech birth, disclosed that adult height was not dependent on the presence of hGH (14 patlents wlth hGH averaged 162.9 cm (SEM 1 .9%), 10 patients without hGH 159.5 cm (SEM 3.49)).
Flowever, adult heights were reached at earller ages (with hGIi at 22.3 y (SEM .%8), wlthout hGH at 25.7 y (SEM . 5 4 ) ) . The duration of the pubertal spurt in growth brought about by androgen treatment was reduced by hCH from 9.5 y (SEM .91) to 5.5 y (SEM .45). Skeletal maturation must have been faster during androgen with hGll than durlng androgen alone. More detalled follow-up studies are needed, particularly in vlew of the Imminent rise In the number of patients that will undergo treatment wlth biosynthetic growth hormone.
Earlier treatment wlth higher or more frequent doses may be required to improve cffectlveness of CII on adult stature. In a previous study we observed that subcutaneously (s.c.) injected human growth hormone (hGH) resulted in significantly lower serum growth hormone profiles (AUC) than after intramusculary (i.m.) administration. In the present study we compared the steady state serum concentrations of continuous infused biosynthetic human growth hormone (B-hGH) via the S.C. and i.v. route in 7 hypopituitary subjects. 6 males and 1 female, mean age 21 years (15-29). The rate of B-hGH infusion was 50 ng/kg/-min. 1.v. infusion was performed for 3 hours, giving a mean steady state concentration of 17.3 ng/ml 2 3.3 (SEM). Following a three hours intermission the s.c. infusion was commenced lasting 19 hours and resulted in significantly lower serum concentration, 5.0 ng/ml + 1.0 (SEM) (p < 0.001). In four of the subjects the S.C. infusion was extended for a further 24 h with a steady state mean serum concentration of 6 ng/ml (p > 0.2). These findings strongly suggest a local subcutaneous degradation of injected hGH in these subjects. The exact mechanisms cannot be deduced from our results but must await further investigation.
